Enlivex (ENLV) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Enlivex Therapeutics Ltd. reported a significant net loss of $9.8 million for the nine months ending September 30, 2024, compared to $19.97 million the previous year. The company’s assets decreased to $29.8 million from $36.8 million at the end of 2023, with a decline in both current and non-current assets. This financial performance reflects ongoing challenges in managing operating expenses, particularly in research and development.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
